TSHA Stock News & Analysis | Latest Updates

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025

August 12, 2025Clinical Trials

TSHA News

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Needham Reiterates Buy on Taysha Gene Therapies, Maintains $8 Price Target

Taysha Gene Therapies To Present Clinical And Preclinical Data Supporting TSHA-102 Rett Syndrome Program, Including Dose Cohort Results, Caregiver Insights Aligning With FDA Endpoints, At IRSF Scientific Meeting June 9–11, 2025 In Boston

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $11

Where Taysha Gene Therapies Stands With Analysts

Needham Reiterates Buy on Taysha Gene Therapies, Raises Price Target to $8

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

JMP Securities Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $6

Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $9

Reported Earlier, Taysha Gene Therapies Prices $200M Public Offering Of Common Stock And Pre-Funded Warrants At $2.75

Taysha Gene Therapies Announces Details Of Its Part B Trial Design For TSHA-102; Announces Clinical Data From Part A Of REVELA Phase 1/2 Adolescent/Adult And Pediatric Trials Evaluating TSHA-102 In Rett Syndrome

Taysha Gene Therapies Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $9

Taysha Gene Therapies Q1 EPS $(0.08) Beats $(0.09) Estimate, Sales $2.30M Beat $1.71M Estimate

JMP Securities Reiterates Market Outperform on Taysha Gene Therapies, Maintains $5 Price Target

Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target

Needham Reiterates Buy on Taysha Gene Therapies, Maintains $6 Price Target

Needham Reinstates Buy on Taysha Gene Therapies, Maintains $6 Price Target

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target

Taysha Gene Therapies Q4 EPS $(0.07) Beats $(0.08) Estimate, Sales $2.02M Miss $2.31M Estimate

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $8

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target

Needham Reiterates Buy on Taysha Gene Therapies, Maintains $6 Price Target

Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target

Taysha Gene Therapies Huge Overhang Removed, Buried In 8-K On Friday; Has Elected Not To Move Forward With A Proposed Offering. Street Average Price Target Is $25 With 1000% Upside; No Offering Could Mean Partnership/Takeout - SEC

Taysha Gene Therapies Says Recently Engaged In Discussions With Various Investors To Explore Potential Equity Financing In Form Of Public Offering, Says Elected Not To Move Forward With Proposed Offering At This Time

Taysha Gene Therapies Receives Orphan Drug Designation From European Commission For TSHA-120 For Treatment Of Giant Axon Neuropathy (GAN)